FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for TALTZ (ixekizumab) by Eli Lilly and Company. This action pertains to a supplemental filing under BLA125521.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• TALTZ (IXEKIZUMAB)

Snippet

SUPPL AP for TALTZ (IXEKIZUMAB)